Skip to content
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Physical Therapy

Managing Your Symptoms and Daily Life

At a Glance

Primary lateral sclerosis has no cure that stops progression, but individualized care can protect comfort and independence. Medicines, physical and occupational therapy, speech and swallowing support, communication tools, and safety planning help manage daily symptoms.

While there is currently no cure or therapy that stops the progression of Primary Lateral Sclerosis (PLS), the disease is highly manageable through targeted symptomatic care. Because PLS moves slowly, your care team has time to focus on preserving your quality of life, comfort, and independence [1][2]. This “symptomatic” approach means that while we cannot yet repair the motor neurons, we can effectively manage the effects of their failure.

Managing Muscle Stiffness (Spasticity)

The most common symptom of PLS is spasticity, or persistent muscle tightness. Management usually begins with oral medications and moves toward more specialized interventions if needed.

  • Oral Medications: Baclofen and tizanidine are common treatments. It is critical to know that these can cause sedation, dizziness, hypotension (low blood pressure), and weakness. Baclofen must not be stopped abruptly because withdrawal can be dangerous; dosing and tapering require clinician supervision [3][4].
  • Botulinum Toxin (Botox): For selected focal muscles, botulinum toxin can provide relief without whole-body side effects [5]. However, it can worsen weakness or swallowing, depending on the muscles treated.
  • Intrathecal Baclofen Pump (ITB): If your stiffness is severe and not well-controlled by pills, your doctor may suggest a baclofen pump. This delivers medication directly into the fluid surrounding your spinal cord [6][7]. An intrathecal pump requires a screening trial and carries surgical, infection, catheter, overdose, and life-threatening withdrawal risks. Pump-maintenance and emergency guidance should be reviewed with your team [4][8].

The Role of PT and OT

Physical Therapy (PT) and Occupational Therapy (OT) are the cornerstones of PLS care. Patients with PLS may benefit from individualized aerobic activity, resistance or functional strengthening, stretching, and range-of-motion work [9][10].

  • Preserving Mobility: PTs focus on gait and balance training to help you walk safely for as long as possible [9]. The goal is to avoid excessive fatigue, pain, falls, or delayed weakness. This includes a PT-supervised, symptom-guided exercise plan with clear advice to stop and report worsening symptoms [11].
  • Preventing Contractures: Ongoing therapy focuses on stretching to prevent permanent joint tightness (contractures) [12].
  • Daily Independence: OTs help you adapt your home and routines—like dressing or cooking—so you can continue them safely [2][10].

Supporting Speech and Swallowing

If your PLS affects your mouth and throat muscles (bulbar symptoms), a Speech-Language Pathologist (SLP) becomes a vital part of your team.

  • Safe Swallowing: Head positioning and texture modification should not be portrayed as universally safe solutions you can try independently. These strategies must follow an individualized SLP assessment and instrumental testing; thickened liquids or restrictive diets can reduce hydration and nutrition. You should have prompt review for aspiration warning signs like recurrent coughing or choking, a wet or gurgly voice after swallowing, recurrent chest infections, or weight loss [13][1].
  • Augmentative Communication: If speech becomes difficult, your team may introduce Augmentative and Alternative Communication (AAC), ranging from letter boards to high-tech devices [14].

Managing Secondary Symptoms

  • Pseudobulbar Affect (PBA): Involuntary laughing or crying can sometimes be managed with dextromethorphan/quinidine (Nuedexta) or certain antidepressants [15][16]. However, evidence specifically in PLS is limited. Quinidine can prolong the QT interval and interact with other medicines, including some antidepressants. Antidepressants are generally an individualized off-label option; patients should not start either approach without a prescriber’s cardiac and medication review [17].
  • Bladder Urgency: Many people experience urinary urgency or frequency [3]. However, significant sphincter symptoms can be a diagnostic red flag, and UTI, retention, medication effects, and spinal disease should be considered before attributing them to PLS.
  • Pain: Managing the stiffness effectively is usually the first step in managing joint and muscle pain [18][3].

Common questions in this guide

How can muscle stiffness from PLS be treated?
Muscle stiffness in PLS is often treated first with oral baclofen or tizanidine. Botulinum toxin may help selected muscles, and a baclofen pump may be considered when severe stiffness is not controlled by pills. These treatments can cause weakness or other side effects, so changes should be supervised by a clinician.
What should I know before considering a baclofen pump for PLS?
A baclofen pump delivers medicine into the fluid around the spinal cord and may be considered when severe stiffness is not controlled well with oral medicine. It requires a screening trial and ongoing maintenance. Surgery, infection, catheter problems, overdose, and dangerous withdrawal are important risks to review with the care team.
What exercise is recommended for people with primary lateral sclerosis?
A physical therapist can create a symptom-guided plan that may include aerobic activity, strengthening, stretching, and range-of-motion exercises. The goal is to support safe movement without excessive fatigue, pain, falls, or delayed weakness. Stop the activity and report worsening symptoms to the therapy or medical team.
How should swallowing changes in PLS be evaluated?
A speech-language pathologist should assess swallowing and may use a test that shows how food and liquid move. Do not independently assume that changing food textures or thickening liquids is safe, because these changes can reduce hydration or nutrition. Recurrent coughing or choking, a wet or gurgly voice, chest infections, or weight loss should prompt a timely clinical review.
What can help when PLS makes speech difficult?
A speech-language pathologist can help plan communication support when speaking becomes difficult. Augmentative and alternative communication may include a letter board or a high-tech speech-generating device. The care team can help select tools that match a person's communication needs.
How is uncontrollable laughing or crying treated in PLS?
Involuntary laughing or crying, called pseudobulbar affect, may be treated with dextromethorphan/quinidine or certain antidepressants. Evidence specifically for PLS is limited, and quinidine can affect the heart's rhythm or interact with other medicines. A prescriber should review heart risks and medications before treatment is started.
Could urinary urgency in PLS have another cause?
Yes. Urgency or frequency may be related to a urinary infection, difficulty emptying the bladder, medication effects, or a spinal problem rather than PLS alone. Significant bladder-control symptoms can be a diagnostic warning sign and should be discussed with a clinician.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Primary lateral sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How much oral baclofen is too much before we should discuss a baclofen pump?
  2. 2.Which specific muscles are most affected by my spasticity, and would botulinum toxin (Botox) injections be a helpful addition?
  3. 3.Can we set an individualized exercise program that balances aerobic, resistance, and stretching work safely?
  4. 4.What are the signs that I should transition from a cane to a walker or wheelchair to prevent falls?
  5. 5.Could my urinary symptoms be related to medications, a UTI, or a spinal issue rather than PLS directly?
  6. 6.What is the plan for my communication—when should I start looking at speech-generating devices?

References

References (18)
  1. 1

    Primary Lateral Sclerosis French National Diagnostic and Care Protocol.

    Corcia P, Bernard E, de la Cruz E, et al.

    Revue neurologique 2026; (182(6)):555-562 doi:10.1016/j.neurol.2026.04.006.

    PMID: 42168009
  2. 2

    Clinical care and therapeutic trials in PLS.

    Floeter MK, Warden D, Lange D, et al.

    Amyotrophic lateral sclerosis & frontotemporal degeneration 2020; (21(sup1)):67-73 doi:10.1080/21678421.2020.1837180.

    PMID: 33602017
  3. 3

    Demographics and clinical characteristics of primary lateral sclerosis: case series and a review of literature.

    Ramanathan RS, Rana S

    Neurodegenerative disease management 2018; (8(1)):17-23 doi:10.2217/nmt-2017-0051.

    PMID: 29316850
  4. 4

    Efficacy and safety of oral baclofen in the management of spasticity: A rationale for intrathecal baclofen.

    Ertzgaard P, Campo C, Calabrese A

    Journal of rehabilitation medicine 2017; (49(3)):193-203 doi:10.2340/16501977-2211.

    PMID: 28233010
  5. 5

    Safety and efficacy of botulinum toxin A for the treatment of spasticity in amyotrophic lateral sclerosis: results of a pilot study.

    Vázquez-Costa JF, Máñez I, Alabajos A, et al.

    Journal of neurology 2016; (263(10)):1954-60 doi:10.1007/s00415-016-8223-z.

    PMID: 27383643
  6. 6

    European expert consensus on improving patient selection for the management of disabling spasticity with intrathecal baclofen and/or botulinum toxin type A.

    Biering-Soerensen B, Stevenson V, Bensmail D, et al.

    Journal of rehabilitation medicine 2022; (54()):jrm00241 doi:10.2340/16501977-2877.

    PMID: 34608495
  7. 7

    Utility of intrathecal baclofen pump in primary lateral sclerosis.

    Zubair AS, Raymond M, Patwa HS

    Journal of the neurological sciences 2021; (420()):117227 doi:10.1016/j.jns.2020.117227.

    PMID: 33239209
  8. 8

    Intrathecal Baclofen to Improve Functional Status in ALS: A Case Report.

    Pressler MP, Cooper PS, Carter W, et al.

    Pain medicine case reports 2023; (7(4)):201-203.

    PMID: 40957031
  9. 9

    Rehabilitation in primary lateral sclerosis mimicking parkinsonism: A case report.

    Moggio L, Petraroli A, Marotta N, et al.

    NeuroRehabilitation 2020; (47(4)):381-386 doi:10.3233/NRE-201527.

    PMID: 33164952
  10. 10

    A Case Report on Robot-Aided Gait Training in Primary Lateral Sclerosis Rehabilitation: Rationale, Feasibility and Potential Effectiveness of a Novel Rehabilitation Approach.

    Portaro S, Ciatto L, Raciti L, et al.

    Innovations in clinical neuroscience 2021; (18(4-6)):15-19.

    PMID: 34980978
  11. 11

    Evolving diagnostic criteria in primary lateral sclerosis: The clinical and radiological basis of "probable PLS".

    Finegan E, Li Hi Shing S, Siah WF, et al.

    Journal of the neurological sciences 2020; (417()):117052 doi:10.1016/j.jns.2020.117052.

    PMID: 32731060
  12. 12

    Best Practices for Intrathecal Baclofen Therapy: Patient Selection.

    Saulino M, Ivanhoe CB, McGuire JR, et al.

    Neuromodulation : journal of the International Neuromodulation Society 2016; (19(6)):607-15 doi:10.1111/ner.12447.

    PMID: 27434197
  13. 13

    Primary lateral sclerosis: diagnosis and management.

    Turner MR, Talbot K

    Practical neurology 2020; (20(4)):262-269 doi:10.1136/practneurol-2019-002300.

    PMID: 32217663
  14. 14

    Effects of Aided Communication on Communicative Participation for People With Amyotrophic Lateral Sclerosis.

    Peters B, Wiedrick J, Baylor C

    American journal of speech-language pathology 2023; (32(4)):1450-1465 doi:10.1044/2023_AJSLP-22-00346.

    PMID: 37335771
  15. 15

    Efficacy and safety of dextromethorphan/quinidine in treating pseudobulbar affect in neurological disorders: A systematic review and dose-classified network meta-analysis.

    Muneer MA, Tariq I, Zulfiqar E, et al.

    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2026; (47(1)):159.

    PMID: 41530593
  16. 16

    Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis.

    Sancho J, Ferrer S, Burés E, et al.

    Respiratory medicine 2021; (186()):106536 doi:10.1016/j.rmed.2021.106536.

    PMID: 34260979
  17. 17

    Pathological laughter and crying in neurological disorders: recognition and treatment.

    Husbands E, Talbot K

    Practical neurology 2022; (22(6)):486-490 doi:10.1136/pn-2021-003301.

    PMID: 35907635
  18. 18

    Non-motor symptoms in motor neuron disease: prevalence, assessment and impact.

    Beswick E, Forbes D, Johnson M, et al.

    Brain communications 2024; (6(1)):fcad336 doi:10.1093/braincomms/fcad336.

    PMID: 38162906

This page is for informational purposes only and does not constitute medical advice. For primary lateral sclerosis, work with your clinician before changing medicines, exercise, swallowing strategies, or communication and mobility equipment.